$HEPA (formerly ContraVir) had a crazy run today on news that their lead asset CRV431 prevented liver cirrhosis in rats in a preclinical study. $LPCN is due to file an IND in December for 1148 in NASH Cirrhosis, as well as the ongoing P2 study for 1144 in NASH. Imagine how the stock price will react if 1144 shows fibrosis reversal IN HUMANS when results are due out end of next year.
  • 3
  • 5